Daratumumab treatment in six highly sensitised solid organ transplant recipients: A case series and literature review.

We report data on six kidney or heart recipients who were administered daratumumab to treat or prevent antibody-mediated rejection (ABMR). To date, data are scarce concerning the use of daratumumab in solid organ transplantation and most reports show a decrease in donor-specific antigen (DSA) levels and an improvement in ABMR using a multiple myeloma daratumumab administration scheme, that is, with sequential systematic administration. Here, we report on the efficacy of daratumumab 1/ in reducing the histological signs of ABMR, 2/ in reducing the ability of DSA to bind to donor cells in vitro through negativation of flow cytometry crossmatching, 3/ in preferentially being directed towards antibodies sharing epitopes, suggesting that daratumumab may specifically target activated plasma cells, 4/ and when administered as a single dose. This last point suggests, for the first time, that, as for rituximab in auto-immune diseases, the scheme for daratumumab administration could be different for targeting DSA-producing plasma cells than for tumour cells.

Characterization of the novel HLA-DQB1*02:01:01:21Q allele by sequencing-based typing.

HLA-DQB1*02:01:01:21Q differs from HLA-DQB1*02:01:01:01 by one nucleotide substitution in the splice site in the beginning of intron 3.

[Update for cord blood unit selection in hematopoietic stem cell transplantation (workshop SFGM-TC)]. / Mise à jour des recommandations pour le choix des unités de sang placentaire en greffe de cellules souches hématopoïétiques (atelier SFGM-TC).

Changing practices and the limited use of cord blood units as a source of cells for allogeneic hematopoietic stem cell transplants (HSC) led us to reconsider the recommendations established in 2011 and 2012, and to propose an update incorporating recent bibliographic data. If HLA compatibility was until now established at low resolution for HLA-A and B loci, and at high resolution for HLA-DRB1, the recent papers are converging towards an increase in the level of resolution, making way for a compatibility now defined in high resolution for all the considered loci, and the inclusion of the HLA-C locus, in order to establish a level of HLA compatibility on 8 alleles (HLA-A, B, C and DRB1). The CD34+ dose is a determining factor in hematopoietic reconstitution but it is not correlated with the total nucleated cells content. This is why we recommend taking these two data into account when choosing a cord blood unit. The recommendations established by our group are presented as a flow chart taking into account the characteristics of the underlying pathology (malignant or non-malignant), the cell dose and the HLA compatibility criteria, as well as criteria linked to the banks in which units are stored.

Characterization of the novel HLA-A*32:177 allele by sequencing-based typing.

HLA-A*32:177 differs from HLA-A*32:01:01:01 by one nucleotide substitution in codon -16 in exon 1.

Characterization of the novel HLA-DPB1*1516:01 allele by sequencing-based typing.

HLA-DPB1*1516:01 differs from HLA-DPB1*1229:01 by seven nucleotide substitutions in exon 3.

Characterization of the novel HLA-DPA1*02:122 allele by sequencing-based typing.

HLA-DPA1*02:122 differs from HLA-DPA1*02:01:01:02 by one nucleotide substitution in codon 78 in exon 2.

Characterization of the novel HLA-DRB3*02:194 allele by sequencing-based typing.

HLA-DRB3*02:194 differs from HLA-DRB3*02:02:01:02 by one nucleotide substitution in codon 78 in exon 2.

Characterization of the novel HLA-B*14:122 allele by sequencing-based typing.

HLA-B*14:122 differs from HLA-B*14:02:01:01 by one nucleotide substitution in codon 102 in exon 3.

Characterization of the novel HLA-C*16:98:02 allele by sequencing-based typing.

HLA-C*16:98:02 differs from HLA-C*16:98:01 by one nucleotide substitution in codon 132 in exon 3.

Characterization of the novel HLA-DRB1*13:03:13 allele by sequencing-based typing.

HLA-DRB1*13:03:13 differs from HLA-DRB1*13:03:01:01 by one nucleotide substitution in codon 180 in exon 3.

Characterization of the novel HLA-B*39:06:09 allele by sequencing-based typing.

HLA-B*39:06:09 differs from HLA-B*39:06:02:01 by one nucleotide substitution in codon 135 in exon 3.

Characterization of the novel HLA-DPA1*01:03:51 allele by sequencing-based typing.

HLA-DPA1*01:03:51 differs from HLA-DPA1*01:03:01:01 by one nucleotide substitution in codon 146 in exon 3.

Characterization of the novel HLA-B*08:312 allele by sequencing-based typing.

HLA-B*08:312 differs from HLA-B*08:01:01:01 by one nucleotide substitution in codon 324 in exon 6.

Characterization of the novel HLA-DRB1*11:324 allele by sequencing-based typing.

HLA-DRB1*11:324 differs from HLA-DRB1*11:62:02 by one nucleotide substitution in codon 38 in exon 2.

Characterization of the novel HLA-DRB3*02:193 allele by sequencing-based typing.

HLA-DRB3*02:193 differs from DRB3*02:02:01:11 by one nucleotide substitution in exon 1, and intronic changes.

Characterization of the novel HLA-B*51:384 allele by sequencing-based typing.

HLA-B*51:384 differs from HLA-B*51:01:01:01 by one nucleotide substitution in codon 267 in exon 4.

Characterization of the novel HLA-DPA1*02:115 allele by sequencing-based typing.

HLA-DPA1*02:115 differs from HLA-DPA1*02:01:01:06 by one nucleotide substitution in codon 224 in exon 4.

Characterization of the novel HLA-DQA1*01:64:02 allele by sequencing-based typing.

HLA-DQA1*01:64:02 differs from HLA-DQA1*01:64:01 by one nucleotide substitution in codon 123 in exon 3.

Characterization of the novel HLA-DQB1*05:01:47 allele by sequencing-based typing.

HLA-DQB1*05:01:47 differs from HLA-DQB1*05:01:01:03 by one nucleotide substitution in codon 144 in exon 3.

Characterization of the novel HLA-B*15:01:01:65Q allele by sequencing-based typing.

HLA-B*15:01:01:65Q differs from HLA-B*15:01:01:01 by one nucleotide substitution in the splice site in the beginning of intron 3.